Literature DB >> 29268036

Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.

Karin P Potoka1,2, Katherine C Wood2,3, Jeffrey J Baust2, Marta Bueno2,4, Scott A Hahn2, Rebecca R Vanderpool2, Tim Bachman2, Grace M Mallampalli2,3, David O Osei-Hwedieh2, Valerie Schrott2, Bin Sun2, Grant C Bullock2, Eva-Maria Becker-Pelster5,6, Matthias Wittwer5, Jan Stampfuss5, Ilka Mathar5, Johannes-Peter Stasch5,7, Hubert Truebel5,6, Peter Sandner5,8, Ana L Mora2,4, Adam C Straub2,9, Mark T Gladwin2,4.   

Abstract

Sickle cell disease (SCD) is associated with intravascular hemolysis and oxidative inhibition of nitric oxide (NO) signaling. BAY 54-6544 is a small-molecule activator of oxidized soluble guanylate cyclase (sGC), which, unlike endogenous NO and the sGC stimulator, BAY 41-8543, preferentially binds and activates heme-free, NO-insensitive sGC to restore enzymatic cGMP production. We tested orally delivered sGC activator, BAY 54-6544 (17 mg/kg/d), sGC stimulator, BAY 41-8543, sildenafil, and placebo for 4-12 weeks in the Berkeley transgenic mouse model of SCD (BERK-SCD) and their hemizygous (Hemi) littermate controls (BERK-Hemi). Right ventricular (RV) maximum systolic pressure (RVmaxSP) was measured using micro right-heart catheterization. RV hypertrophy (RVH) was determined using Fulton's index and RV corrected weight (ratio of RV to tibia). Pulmonary artery vasoreactivity was tested for endothelium-dependent and -independent vessel relaxation. Right-heart catheterization revealed higher RVmaxSP and RVH in BERK-SCD versus BERK-Hemi, which worsened with age. Treatment with the sGC activator more effectively lowered RVmaxSP and RVH, with 90-day treatment delivering superior results, when compared with other treatments and placebo groups. In myography experiments, acetylcholine-induced (endothelium-dependent) and sodium-nitroprusside-induced (endothelium-independent NO donor) relaxation of the pulmonary artery harvested from placebo-treated BERK-SCD was impaired relative to BERK-Hemi but improved after therapy with sGC activator. By contrast, no significant effect for sGC stimulator or sildenafil was observed in BERK-SCD. These findings suggest that sGC is oxidized in the pulmonary arteries of transgenic SCD mice, leading to blunted responses to NO, and that the sGC activator, BAY 54-6544, may represent a novel therapy for SCD-associated pulmonary arterial hypertension and cardiac remodeling.

Entities:  

Keywords:  pulmonary hypertension; sickle cell disease; soluble guanylate cyclase

Mesh:

Substances:

Year:  2018        PMID: 29268036      PMCID: PMC5946331          DOI: 10.1165/rcmb.2017-0292OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  65 in total

1.  Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.

Authors:  Erland Erdmann; Marc J Semigran; Markku S Nieminen; Mihai Gheorghiade; Rahul Agrawal; Veselin Mitrovic; Alexandre Mebazaa
Journal:  Eur Heart J       Date:  2012-07-09       Impact factor: 29.983

2.  Heme oxygenase-1 is a cGMP-inducible endothelial protein and mediates the cytoprotective action of nitric oxide.

Authors:  T Polte; A Abate; P A Dennery; H Schröder
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-05       Impact factor: 8.311

3.  Platelet bioenergetic screen in sickle cell patients reveals mitochondrial complex V inhibition, which contributes to platelet activation.

Authors:  Nayra Cardenes; Catherine Corey; Lisa Geary; Shilpa Jain; Sergey Zharikov; Suchitra Barge; Enrico M Novelli; Sruti Shiva
Journal:  Blood       Date:  2014-03-27       Impact factor: 22.113

4.  Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels.

Authors:  Johannes-Peter Stasch; Peter M Schmidt; Pavel I Nedvetsky; Tatiana Y Nedvetskaya; Arun Kumar H S; Sabine Meurer; Martin Deile; Ashraf Taye; Andreas Knorr; Harald Lapp; Helmut Müller; Yagmur Turgay; Christiane Rothkegel; Adrian Tersteegen; Barbara Kemp-Harper; Werner Müller-Esterl; Harald H H W Schmidt
Journal:  J Clin Invest       Date:  2006-09       Impact factor: 14.808

5.  Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse.

Authors:  D K Kaul; X D Liu; M E Fabry; R L Nagel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-06       Impact factor: 4.733

6.  Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.

Authors:  Diana Bonderman; Stefano Ghio; Stephan B Felix; Hossein-Ardeschir Ghofrani; Evangelos Michelakis; Veselin Mitrovic; Ronald J Oudiz; Francis Boateng; Andrea-Viviana Scalise; Lothar Roessig; Marc J Semigran
Journal:  Circulation       Date:  2013-06-17       Impact factor: 29.690

7.  Vasculopathy, inflammation, and blood flow in leg ulcers of patients with sickle cell anemia.

Authors:  Caterina P Minniti; Kara-Marie H Delaney; Alexander M Gorbach; Dihua Xu; Chyi-Chia Richard Lee; Nitin Malik; Antony Koroulakis; Matthew Antalek; Jordan Maivelett; Marlene Peters-Lawrence; Enrico M Novelli; Sophie M Lanzkron; Karen C Axelrod; Gregory J Kato
Journal:  Am J Hematol       Date:  2013-09-19       Impact factor: 10.047

8.  Direct sGC activation bypasses NO scavenging reactions of intravascular free oxy-hemoglobin and limits vasoconstriction.

Authors:  Nicolaas J H Raat; D Marcela Tabima; Patricia A C Specht; Jesús Tejero; Hunter C Champion; Daniel B Kim-Shapiro; Jeff Baust; Egbert G Mik; Mariana Hildesheim; Johannes-Peter Stasch; Eva-Maria Becker; Hubert Truebel; Mark T Gladwin
Journal:  Antioxid Redox Signal       Date:  2013-07-09       Impact factor: 8.401

9.  Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.

Authors:  Mihai Gheorghiade; Stephen J Greene; Javed Butler; Gerasimos Filippatos; Carolyn S P Lam; Aldo P Maggioni; Piotr Ponikowski; Sanjiv J Shah; Scott D Solomon; Elisabeth Kraigher-Krainer; Eliana T Samano; Katharina Müller; Lothar Roessig; Burkert Pieske
Journal:  JAMA       Date:  2015-12-01       Impact factor: 56.272

10.  Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease.

Authors:  John D Belcher; Chunsheng Chen; Julia Nguyen; Liming Milbauer; Fuad Abdulla; Abdu I Alayash; Ann Smith; Karl A Nath; Robert P Hebbel; Gregory M Vercellotti
Journal:  Blood       Date:  2013-11-25       Impact factor: 22.113

View more
  11 in total

Review 1.  New insights into the pathophysiology and development of novel therapies for sickle cell disease.

Authors:  Scott Moerdler; Deepa Manwani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  cGMP modulation therapeutics for sickle cell disease.

Authors:  Nicola Conran; Lidiane Torres
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-28

3.  Rescuing Decrepit Soluble Guanylate Cyclase: A Therapy for Sickle Cell Disease?

Authors:  Paul T Schumacker
Journal:  Am J Respir Cell Mol Biol       Date:  2018-05       Impact factor: 6.914

Review 4.  Redox regulation of soluble guanylyl cyclase.

Authors:  Rohan C Shah; Subramaniam Sanker; Katherine C Wood; Brittany G Durgin; Adam C Straub
Journal:  Nitric Oxide       Date:  2018-03-22       Impact factor: 4.427

5.  Sickle cell disease subjects and mouse models have elevated nitrite and cGMP levels in blood compartments.

Authors:  Luis E F Almeida; Sayuri Kamimura; Celia M de Souza Batista; Nicholas Spornick; Margaret Y Nettleton; Elizabeth Walek; Meghann L Smith; Julia C Finkel; Deepika S Darbari; Paul Wakim; Zenaide M N Quezado
Journal:  Nitric Oxide       Date:  2019-11-02       Impact factor: 4.427

6.  Soluble Guanylate Cyclase Stimulators and Activators.

Authors:  Peter Sandner; Daniel P Zimmer; G Todd Milne; Markus Follmann; Adrian Hobbs; Johannes-Peter Stasch
Journal:  Handb Exp Pharmacol       Date:  2021

7.  Smooth muscle cytochrome b5 reductase 3 deficiency accelerates pulmonary hypertension development in sickle cell mice.

Authors:  Katherine C Wood; Brittany G Durgin; Heidi M Schmidt; Scott A Hahn; Jeffrey J Baust; Tim Bachman; Dario A Vitturi; Samit Ghosh; Solomon F Ofori-Acquah; Ana L Mora; Mark T Gladwin; Adam C Straub
Journal:  Blood Adv       Date:  2019-12-10

Review 8.  Redox Switches Controlling Nitric Oxide Signaling in the Resistance Vasculature and Implications for Blood Pressure Regulation: Mid-Career Award for Research Excellence 2020.

Authors:  Atinuke Aramide Modupe Dosunmu-Ogunbi; Joseph C Galley; Shuai Yuan; Heidi M Schmidt; Katherine C Wood; Adam C Straub
Journal:  Hypertension       Date:  2021-08-23       Impact factor: 9.897

Review 9.  Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure.

Authors:  Katherine C Wood; Mark T Gladwin; Adam C Straub
Journal:  Heart       Date:  2019-12-10       Impact factor: 5.994

Review 10.  Multiple inducers of endothelial NOS (eNOS) dysfunction in sickle cell disease.

Authors:  Robert P Hebbel; Gregory M Vercellotti
Journal:  Am J Hematol       Date:  2021-08-23       Impact factor: 13.265

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.